Johnson & Johnson at a Glance

Uppers

  • The world's largest and most diverse medical device and diagnostics company
  • Great brand cachet for future résumés
  • Nationally recognized as a great place to work

Downers

  • Profits and revenues have suffered in recent years
  • Lay-offs are a fact of life at J&J
  • Large-scale recalls for consumer products in recent years

The Bottom Line

  • Johnson & Johnson is leading provider of consumer health, pharmaceutical and device products. It's also a leading employer, with a reputation for treating employees well.

About Johnson & Johnson

It's difficult to get well without Johnson & Johnson (J&J). The diversified health care giant operates in three segments through more than 250 operating companies located in some 60 countries. Its Medical Devices division offers surgical equipment, monitoring devices, orthopedic and insulin delivery products, and contact lenses, among other things. J&J's Pharmaceuticals division makes drugs for an array of ailments, such as neurological conditions, blood disorders, autoimmune diseases, and pain. Top sellers are psoriasis drug Remicade and cancer medication Velcade. Finally, J&J's Consumer business makes over-the-counter (OTC) drugs and products for baby, skin, and oral care, as well as first-aid and nutritional uses.

Operations

J&J prides itself on its decentralized operating structure, with the management teams of its myriad and far-flung operating units having wide latitude to make decisions. Each company belongs to one of J&J's three broad divisions: The Pharmaceuticals and Medical Devices segments account for about 45% and 35% of sales, respectively, while the Consumer division contributes about 20% of annual revenues. J&J's diversified business model also allows for some insulation against troubles in any one market.

In its Medical Devices division, many operating companies -- including surgical supplies companies Ethicon and Ethicon Endo-Surgery, orthopedics device maker DePuy, and vision care subsidiary Vision Care-- have experienced strong sales growth. The division also includes the LifeScan diabetes care unit.

Operating companies in the Pharmaceuticals division include Janssen Biotech and Janssen Pharmaceuticals. Remicade is the company's top earner, bringing in about $7 billion in annual sales or some 10% of total revenue; in addition to psoriasis, the drug treats Crohn's disease, rheumatoid arthritis, and ulcerative colitis. In addition, key drugs earning over $1 billion annually are Procrit (sold internationally as Eprex), schizophrenia medication Invega Sustenna/Xeplion/Invega Trinza, cancer treatment Velcade, AIDS therapy Prezista, and plaque psoriasis drug Stelara.

The Consumer segment sells products including J&J's baby products, the Listerine brand of oral care products, and skin care brands including Aveeno, Clean & Clear, and Neutrogena.

Geographic Reach

J&J has more than 250 operating companies in 60 countries selling products around the world. It has research facilities in more than a dozen countries and operates about 120 manufacturing facilities in North America, Asia, Europe, and the Middle East.

While the US and Europe represent the company's largest markets (accounting for more than 50% and about 25% of sales, respectively), the firm has been working to expand its presence in markets in Asia (especially China) and other regions that are emerging as high-growth opportunities. The Asia/Pacific region and Africa together account for more than 15% of revenue, while the non-US Western Hemisphere accounts for about 10%.

 

Sales and Marketing

J&J distributes its products to retailers, wholesalers, and health care providers including hospitals.

Medical devices are marketed to the orthopedic, surgery, cardiovascular, diabetes care, and vision care industries. They are distributed to wholesalers, hospitals, and retailers.

The company spent $2.4 billion on advertising campaigns (including television, radio, print, and online ads) in fiscal 2017; this was down from $2.5 spent in 2015 and $2.6 billion spent in 2014.

Financial Performance

J&J had seen steady revenue growth over the past few years, but in fiscal 2016 (ended January) revenue dropped 6% to $70.1 billion. It recovered 3% to $71.9 billion in fiscal 2017. This was due to a 6% increase in pharmaceuticals sales, but was partially offset by declines in medical device and consumer product sales. In pharmaceuticals, strong performers included Remicade (despite competition from biosimilar versions of the drug), Simponi, Stelara, Imbruvica, and Edurant. Net income has followed revenue's suit, rising until 2016 when it fell 6% to $15.4 billion. In 2017 it rose 7%$16.5 billion.

Cash flow from operations declined 3% to $18.8 billion in fiscal 2017 due to factors including a decrease in current and non-current liabilities.

Strategy

J&J's core strategies for growth are to create value through innovation, expand its international reach, execute with excellence, and lead with purpose. It has worked toward these goals through such efforts as embracing health care technology, acquiring new businesses (such as Abbott Medical Optics, purchased in early 2017), and strategically divesting certain units. In the pharmaceuticals business, J&J is focused on innovating in therapeutic areas where the medical needs are largely unmet. It spends some $5.4 billion on its R&D pipeline annually, seeking new treatments as well as new indications for existing products. The company hopes to launch 10 blockbusters, or products that will top $1 billion in annual sales, by 2019. It also fights to keep its drugs competitive by protecting its patents against the releases of biosimilars.

J&J also plans to launch innovative products through its consumer and medical device segments. It has expanded those segments through recent acquisitions, and it is improving margins by utilizing supply chain and operational efficiencies.

However, in early 2016 J&J announced plans to restructure the Medical Devices segment over the next two years, as the company deals with changes in the global medical device market's landscape. The changes will affect the unit's orthopedics, surgery, and cardiovascular operations, but not its consumer medical devices, vision care, or diabetes care operations. The company expects the restructuring to bring in some $800 million to $1 billion in annual savings.

In the consumer segment, J&J's top sellers include Tylenol and Motrin. The company is also counting on its Neutrogena, Listerine, and Johnson's Baby brands to deliver growth for the segment going forward.

To narrow its focus on core businesses in high-demand product areas, in 2015 J&J sold cardiovascular products maker Cordis to Cardinal Health in a $1.94 billion transaction. The company also sold the US license rights to Nucynta to Depomed for $1.1 billion.

Also in 2015, J&J established surgical solutions firm Verb Surgical in collaboration with Verily Life Sciences (formerly Google Life Sciences).

Mergers and Acquisitions

While it continues to streamline its businesses for optimal performance, J&J is also keeping pace with its acquisition strategy by pursuing company purchases both large and small.

In late 2015, J&J acquired Novira Therapeutics, a clinical-stage company working on treatments for chronic Hepatitis B infections. That firm, which is testing small molecule NVR 3-778, is now part of Janssen Pharmaceuticals' infectious diseases and vaccines segment.

Other 2015 deals include the purchases of medical device firms NeuWave Medical and Coherex Medical and hepatitis B specialist Novira Therapeutics,

Johnson & Johnson Consumer bought Vogue International for $3.3 billion in mid-2016. Vogue develops, markets, and distributes personal care lines such as the OGX brand of hair care and other products. The segment also acquired NeoStrata, which makes dermocosmetics.

In early 2017 the company acquired Abbott Medical Optics from Abbott Laboratories for $4.3 billion. That purchase, which included operations in cataract surgery, laser vision surgery, and consumer products such as eye drops, underscored J&J's growing focus on vision. Furthering that mission, the company acquired medical device maker TearScience in 2017. TearScience manufactures devices designed to treat Meibomian Gland Disfunction, the leading cause of dry eye disease. J&J also acquired Sightbox, an online subscription service for contact lens wearers.

Also in 2017, J&J bought Swiss biotech Actelion, which focuses on rare diseases, for $30 billion. That deal added Actelion's treatments for pulmonary arterial hypertension to its portfolio. As part of the transaction, J&J spun off Actelion's drug discovery and early-stage R&D operations into a new public Swiss company.

The company additionally secured the rights to Protagonist Therapeutics' PTG-200, a pre-clinical oral therapy for Crohn's disease, for up to $990 million.

- Show Less + Show Full Description

Company News and Press Releases

- Show Less + Show More News and Press Releases

Johnson & Johnson

1 Johnson And Johnson Plz
New Brunswick, NJ 08933-0002
Phone: 1 (732) 524-0400
Fax: 1 (732) 524-0332

Stats

  • Employer Type: Public
  • Stock Symbol: JNJ
  • Stock Exchange: NYSE
  • Chairman and CEO: Alex Gorsky
  • Chairman and CEO: Alex Gorsky
  • EVP and Group Worldwide Chairman: Sandra E. Peterson
  • 2017 Employees: 126,400

Major Office Locations

  • New Brunswick, NJ
  • Neenah, WI

Other Locations

  • Maylene, AL
  • Mobile, AL
  • Baldwin Park, CA
  • Cottonwood, CA
  • Folsom, CA
  • Fontana, CA
  • Fremont, CA
  • Irvine, CA
  • Irwindale, CA
  • Los Angeles, CA
  • Los Gatos, CA
  • Milpitas, CA
  • Mountain View, CA
  • Sacramento, CA
  • San Diego, CA
  • Santa Ana, CA
  • Santa Barbara, CA
  • Santa Monica, CA
  • Sunnyvale, CA
  • Vacaville, CA
  • Englewood, CO
  • Monument, CO
  • Simsbury, CT
  • Southington, CT
  • Washington, DC
  • Wilmington, DE
  • Boca Raton, FL
  • Dania Beach, FL
  • Miami, FL
  • Naples, FL
  • Orlando, FL
  • Palm Beach Gardens, FL
  • Sarasota, FL
  • Athens, GA
  • Cornelia, GA
  • Macon, GA
  • Peachtree City, GA
  • Sylvester, GA
  • Stuart, IA
  • Buffalo Grove, IL
  • Chicago, IL
  • Inverness, IL
  • Loves Park, IL
  • Fishers, IN
  • Indianapolis, IN
  • Mooresville, IN
  • Warsaw, IN
  • Lenexa, KS
  • Overland Park, KS
  • Lexington, KY
  • Louisville, KY
  • Richmond, KY
  • Baton Rouge, LA
  • Mandeville, LA
  • Monroe, LA
  • Bridgewater, MA
  • Norton, MA
  • Raynham, MA
  • West Springfield, MA
  • Baltimore, MD
  • Rockville, MD
  • Ann Arbor, MI
  • Orion, MI
  • Troy, MI
  • Minneapolis, MN
  • Moorhead, MN
  • Canton, MO
  • Joliet, MT
  • Charlotte, NC
  • Greensboro, NC
  • Omaha, NE
  • Bedminster, NJ
  • Branchburg, NJ
  • Bridgewater, NJ
  • Lambertville, NJ
  • Monroe Township, NJ
  • Morris Plains, NJ
  • New Providence, NJ
  • North Brunswick, NJ
  • Piscataway, NJ
  • Plainsboro, NJ
  • Princeton, NJ
  • Raritan, NJ
  • Ridgefield, NJ
  • Skillman, NJ
  • Somerset, NJ
  • Somerville, NJ
  • Titusville, NJ
  • Trenton, NJ
  • Warren, NJ
  • Albuquerque, NM
  • Albany, NY
  • Buffalo, NY
  • Horseheads, NY
  • North Tonawanda, NY
  • Rochester, NY
  • Wantagh, NY
  • Blue Ash, OH
  • Cincinnati, OH
  • Dayton, OH
  • Lucasville, OH
  • Medina, OH
  • Norman, OK
  • Oklahoma City, OK
  • Tulsa, OK
  • Chesterbrook, PA
  • Doylestown, PA
  • Exton, PA
  • Fort Washington, PA
  • Huntingdon Valley, PA
  • Lancaster, PA
  • Lititz, PA
  • Malvern, PA
  • New Kensington, PA
  • Paoli, PA
  • Philadelphia, PA
  • Radnor, PA
  • Reading, PA
  • Royersford, PA
  • Seven Fields, PA
  • Spring House, PA
  • Tobyhanna, PA
  • West Chester, PA
  • Wexford, PA
  • Gurabo, PR
  • San Lorenzo, PR
  • Cumberland, RI
  • Foster, RI
  • Blythewood, SC
  • Columbia, SC
  • Hopkins, SC
  • Franklin, TN
  • Memphis, TN
  • Austin, TX
  • El Paso, TX
  • Flower Mound, TX
  • Fresno, TX
  • Houston, TX
  • Irving, TX
  • Kingwood, TX
  • Richardson, TX
  • San Angelo, TX
  • Tyler, TX
  • Cornell, WI
  • Schwechat, Austria
  • Antwerpen, Belgium
  • Beerse, Belgium
  • Bruxelles, Belgium
  • Courcelles, Belgium
  • Geel, Belgium
  • La Louvière, Belgium
  • Machelen (Bt.), Belgium
  • Olen, Belgium
  • Turnhout, Belgium
  • Vosselaar, Belgium
  • Rio De Janeiro, Brazil
  • Calgary, Canada
  • Fabreville, Canada
  • Garson, Canada
  • Guelph, Canada
  • Westbank, Canada
  • Windsor, Canada
  • Beijing, China
  • Changchun, China
  • Chengdu, China
  • Guangzhou, China
  • Hangzhou, China
  • Nanjing, China
  • Shanghai, China
  • Wuhan, China
  • Birkerød, Denmark
  • Hellerup, Denmark
  • Espoo, Finland
  • Boulogne Billancourt, France
  • Chartres, France
  • Dijon, France
  • Illkirch Graffenstaden, France
  • Saint Priest, France
  • Sezanne, France
  • Val De Reuil, France
  • Neckargemünd, Germany
  • Neuss, Germany
  • Norderstedt, Germany
  • Tuttlingen, Germany
  • Mandra, Greece
  • Thermi, Greece
  • 24 South Parganas, India
  • Ahmedabad, India
  • Amritsar, India
  • Auranagabad, India
  • Baddi, India
  • Bengaluru, India
  • Bhiwadi, India
  • Chandigarh, India
  • Chennai, India
  • Ernakulam, India
  • Ghaziabad, India
  • Gurgaon, India
  • Guwahati, India
  • Howrah, India
  • Hyderabad, India
  • Jaipur, India
  • Kanpur, India
  • Kolkata, India
  • Manipal, India
  • Mumbai, India
  • Navi Mumbai, India
  • New Delhi, India
  • Pune, India
  • Secunderabad, India
  • Thane, India
  • Vapi, India
  • Visakhapatnam, India
  • Aprilia, Italy
  • Cologno Monzese, Italy
  • Latina, Italy
  • Milano, Italy
  • Opera, Italy
  • Chiyoda-Ku, Japan
  • Fukuoka, Japan
  • Hiroshima, Japan
  • Inashiki-Gun, Japan
  • Itabashi-Ku, Japan
  • Kanazawa, Japan
  • Kawasaki, Japan
  • Kobe, Japan
  • Koto-Ku, Japan
  • Kuki, Japan
  • Kyoto, Japan
  • Minato-Ku, Japan
  • Misato, Japan
  • Nagoya, Japan
  • Okayama, Japan
  • Osaka, Japan
  • Saitama, Japan
  • Sapporo, Japan
  • Sendai, Japan
  • Shinagawa-Ku, Japan
  • Sukagawa, Japan
  • Sunto-Gun, Japan
  • Takamatsu, Japan
  • Huejotzingo, Mexico
  • Monterrey, Mexico
  • Oslo, Norway
  • Coimbra, Portugal
  • Porto, Portugal
  • Moscow, Russia
  • Novosibirsk, Russia
  • Neuchâtel, Switzerland
  • Zug, Switzerland
- Show Less + Show More